Literature DB >> 9504449

Nephrolithiasis and risk of hypertension.

F Madore1, M J Stampfer, E B Rimm, G C Curhan.   

Abstract

A positive association between nephrolithiasis and blood pressure has been suggested in previous studies. However, controversy remains, due to methodological problems in some of the previous studies and absence of prospective data. We evaluated the relationship between nephrolithiasis and the risk of hypertension in a cohort of 51,529 men followed prospectively for 8 years. Information was obtained by biennial mailed questionnaires. At baseline in 1986, 4111 (8.0%) subjects reported a history of nephrolithiasis and 11,623 (22.6%) a diagnosis of hypertension. A positive association was found between the two disorders (age adjusted odds ratio [OR]: 1.31; 95% confidence interval [CI]: 1.30 to 1.32). Among men who reported both disorders, 79.5% reported that the occurrence of nephrolithiasis was prior to or concomitant with the diagnosis of hypertension. Among men without hypertension at baseline, the odds ratio for incident hypertension in men with a history of nephrolithiasis compared with those without was 1.29 (95% CI: 1.12 to 1.41; adjusted for age, body mass index, and intake of calcium, sodium, potassium, magnesium, and alcohol). The occurrence of incident nephrolithiasis during follow-up was similar in men with hypertension at baseline compared with that in men without (adjusted OR: 0.99, 95% CI: 0.82 to 1.21). These data support the hypothesis that prior occurrence of nephrolithiasis increases the risk of subsequent hypertension.

Entities:  

Mesh:

Year:  1998        PMID: 9504449     DOI: 10.1016/s0895-7061(97)00371-3

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  64 in total

1.  Risk of Nephrolithiasis in Patients With Sleep Apnea: A Population-Based Cohort Study.

Authors:  Sheng-Han Tsai; Marshall L Stoller; Benjamin A Sherer; Zi-Hao Chao; Tao-Hsin Tung
Journal:  J Clin Sleep Med       Date:  2018-05-15       Impact factor: 4.062

2.  [Economic aspects of evidence-based metaphylaxis].

Authors:  W L Strohmaier
Journal:  Urologe A       Date:  2006-11       Impact factor: 0.639

3.  Clinical characteristics of potential kidney donors with asymptomatic kidney stones.

Authors:  Elizabeth C Lorenz; John C Lieske; Terri J Vrtiska; Amy E Krambeck; Xujian Li; Eric J Bergstralh; L Joseph Melton; Andrew D Rule
Journal:  Nephrol Dial Transplant       Date:  2011-02-01       Impact factor: 5.992

4.  A decrease in blood pressure following pyelolithotomy but not extracorporeal lithotripsy.

Authors:  Davor Eterović; Marijan Situm; Ljubica Juretić-Kuscić; Zeljko Dujić
Journal:  Urol Res       Date:  2004-12-24

5.  Risk of Hypertension among First-Time Symptomatic Kidney Stone Formers.

Authors:  Wonngarm Kittanamongkolchai; Kristin C Mara; Ramila A Mehta; Lisa E Vaughan; Aleksandar Denic; John J Knoedler; Felicity T Enders; John C Lieske; Andrew D Rule
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 8.237

Review 6.  Kidney stone disease.

Authors:  Fredric L Coe; Andrew Evan; Elaine Worcester
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

7.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

Review 8.  Kidney stones: an update on current pharmacological management and future directions.

Authors:  Hongshi Xu; Anna L Zisman; Fredric L Coe; Elaine M Worcester
Journal:  Expert Opin Pharmacother       Date:  2013-03       Impact factor: 3.889

Review 9.  Epidemiology of stone disease across the world.

Authors:  Igor Sorokin; Charalampos Mamoulakis; Katsuhito Miyazawa; Allen Rodgers; Jamsheer Talati; Yair Lotan
Journal:  World J Urol       Date:  2017-02-17       Impact factor: 4.226

Review 10.  Nephrolithiasis and hypertension: possible links and clinical implications.

Authors:  Adamasco Cupisti; Claudia D'Alessandro; Sara Samoni; Mario Meola; Maria Francesca Egidi
Journal:  J Nephrol       Date:  2014-02-28       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.